Prothena Corp. (NASDAQ:PRTA) shares were up 6.5% on Wednesday . The stock traded as high as $51.93 and last traded at $51.92, with a volume of 196,489 shares traded. The stock had previously closed at $48.74.

Several research analysts have recently weighed in on PRTA shares. Credit Suisse Group AG reiterated a “buy” rating on shares of Prothena Corp. in a research note on Tuesday, July 12th. Royal Bank Of Canada restated an “outperform” rating and set a $95.00 price objective on shares of Prothena Corp. in a research report on Monday. Zacks Investment Research upgraded shares of Prothena Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, April 21st. Barclays PLC initiated coverage on shares of Prothena Corp. in a research report on Friday, May 13th. They set an “overweight” rating and a $60.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $77.00 price objective on shares of Prothena Corp. in a research report on Tuesday, July 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $74.60.

The stock’s 50 day moving average price is $43.88 and its 200 day moving average price is $41.83. The company’s market cap is $1.83 billion.

Prothena Corp. (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.04. Analysts predict that Prothena Corp. will post ($3.72) earnings per share for the current year.

In other Prothena Corp. news, Director Dennis J. Selkoe sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $45.00, for a total transaction of $225,000.00. Following the transaction, the director now owns 3,025 shares in the company, valued at approximately $136,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A number of hedge funds and institutional investors recently modified their holdings of the stock. State Board of Administration of Florida Retirement System raised its position in shares of Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock worth $1,182,000 after buying an additional 803 shares during the last quarter. Nationwide Fund Advisors increased its stake in Prothena Corp. by 77.8% in the fourth quarter. Nationwide Fund Advisors now owns 35,835 shares of the company’s stock valued at $2,441,000 after buying an additional 15,683 shares during the period. California State Teachers Retirement System increased its stake in Prothena Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 57,940 shares of the company’s stock valued at $3,946,000 after buying an additional 900 shares during the period. Rhumbline Advisers increased its stake in Prothena Corp. by 7.5% in the fourth quarter. Rhumbline Advisers now owns 30,805 shares of the company’s stock valued at $2,098,000 after buying an additional 2,140 shares during the period. Finally, California Public Employees Retirement System increased its stake in Prothena Corp. by 214.0% in the fourth quarter. California Public Employees Retirement System now owns 91,700 shares of the company’s stock valued at $6,246,000 after buying an additional 62,500 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.